Globus Medical, Inc. (GMED) Downgraded to Market Perform by BMO Capital

Market Context

Globus Medical, Inc. operates in the Healthcare sector. The stock currently trades at $73.89 with a market capitalization of $11.9B. The stock has gained 42.3% over the past 52 weeks.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow BMO Capital's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Globus Medical, Inc.

Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 06, 2026	Wells Fargo	Overweight	N/A
Nov 06, 2026	Needham	Buy	N/A
Nov 06, 2026	BMO Capital	Market Perform	N/A
Oct 01, 2026	RBC Capital	Outperform	N/A
Aug 07, 2026	Wells Fargo	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View GMED Stock Page